HC Wainwright Issues Positive Outlook for Immunic Earnings

Posted by on Aug 19th, 2026

Immunic, Inc. (NASDAQ:IMUX – Free Report) – Equities research analysts at HC Wainwright increased their Q3 2026 earnings estimates for shares of Immunic in a report released on Thursday, August 13th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.74) per share for the quarter, up from their prior estimate of ($2.21). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Immunic’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Immunic’s Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($3.18) EPS, FY2027 earnings at ($2.47) EPS, FY2028 earnings at ($1.45) EPS, FY2029 earnings at ($0.53) EPS and FY2030 earnings at $0.40 EPS.

Immunic (NASDAQ:IMUX – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.36.

A number of other equities research analysts have also recently weighed in on the stock. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a report on Wednesday, July 29th. B. Riley Financial dropped their price target on Immunic from $40.00 to $27.00 and set a “buy” rating on the stock in a research report on Friday, May 22nd. Wall Street Zen upgraded Immunic from a “sell” rating to a “hold” rating in a research note on Saturday. Roth Capital restated a “buy” rating and issued a $19.00 price target on shares of Immunic in a research note on Thursday, May 14th. Finally, Wolfe Research assumed coverage on Immunic in a research report on Friday, May 22nd. They set an “outperform” rating for the company. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Immunic currently has an average rating of “Buy” and a consensus target price of $47.25.

Check Out Our Latest Research Report on Immunic

Immunic Price Performance

Shares of NASDAQ IMUX opened at $16.90 on Monday. Immunic has a 1 year low of $5.06 and a 1 year high of $17.17. The firm has a 50-day moving average of $14.63 and a 200 day moving average of $12.24. The stock has a market cap of $230.52 million, a P/E ratio of -3.86 and a beta of 1.41.

Institutional Trading of Immunic

A number of institutional investors and hedge funds have recently modified their holdings of IMUX. CTC Alternative Strategies Ltd. bought a new stake in Immunic in the 1st quarter worth approximately $27,000. ADAR1 Capital Management LLC bought a new position in shares of Immunic during the 1st quarter valued at $33,000. Qube Research & Technologies Ltd bought a new position in shares of Immunic during the 3rd quarter valued at $29,000. Focus Partners Wealth lifted its holdings in shares of Immunic by 1.5% during the 3rd quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock valued at $2,276,000 after buying an additional 39,063 shares during the period. Finally, Two Sigma Investments LP purchased a new position in shares of Immunic in the 3rd quarter worth $52,000. Institutional investors own 51.82% of the company’s stock.

About Immunic

(Get Free Report)

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.

Featured Articles

Earnings History and Estimates for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.